Evidence map›Paper›PMID 35443023›Full record

ArticleBlood advances2022

MicroRNA serum profiles and chronic graft-versus-host disease.

Håkon Reikvam, Anh Khoi Vo, Silje Johansen, Anette Lodvir Hemsing, Magne Haugland Solheim, Knut Anders Mosevoll, Tor Henrik Anderson Tvedt, Kimberley Joanne Hatfield

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Håkon ReikvamDepartment of Clinical Science, University of Bergen, Bergen, Norway.ORCID 0000-0001-5439-8411
Anh Khoi VoDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Silje JohansenDepartment of Clinical Science, University of Bergen, Bergen, Norway.ORCID 0000-0003-1373-2414
Anette Lodvir HemsingDepartment of Clinical Science, University of Bergen, Bergen, Norway.ORCID 0000-0002-1567-1099
Magne Haugland SolheimDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Knut Anders MosevollDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Tor Henrik Anderson TvedtDepartment of Medicine, Haukeland University Hospital, Bergen, Norway; and.
Kimberley Joanne HatfieldDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Haukeland University Hospital · NOUniversity of Bergen · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic graft-versus-host disease (cGVHD) is the most common long-term complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). During the last decade, the interest of micro RNAs (miRNAs) in the pathophysiological process of cGVHD has increased. The objectives of this study were to investigate a wide range of serum miRNAs in allografted patients and identify associations between miRNAs and cGVHD. The study included 79 allotransplanted adults, where serum samples were obtained 1 year after the allo-HSCT, and miRNA profiling analysis in serum was performed. Fifty of the 79 patients (63%) had signs of cGVHD at the 1-year post-allo-HSCT control. miRNA sequencing analysis revealed 1380 different miRNAs detected for at least 1 patient, whereas 233 miRNAs (17%) were detected in >70 patients. We identified 10 miRNAs that differed significantly between patients with and without cGVHD (P < .005; false discovery rate <0.1), and all of these miRNAs were detected for >75 of the patients. Furthermore, 5 distinct miRNAs, miR-365-3p, miR-148-3p, miR-122-5p, miR-378-3p, and miR-192-5p, were found to be particularly associated with cGVHD in our analysis and were validated by receiver operating characteristics analysis. Based on only 3 miRNAs, miR-365-3p, miR-148-3p, and miR-378-3p, we developed a miRNA signature that, by bioinformatic approaches and linear regression model, utterly improved our potential diagnostic biomarker model for cGVHD. We conclude that miRNAs are differently expressed among patients with and without cGVHD, although further and larger studies are needed to validate our present findings.

Indexed as

Graft vs Host DiseaseMicroRNAsAdultBiomarkersComputational BiologyGene Expression ProfilingHumansBiomarkersMicroRNAsMIRN365 microRNA, human

Identifiers

PMID35443023
PMCPMC9631696
OpenAlexW4224236949

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.